Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Regulatory press release 2022-06-15

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that the company has appointed Thomas Walz to the newly established position Chief Medical Officer (CMO). Thomas joins Xspray Pharma from a senior role at GSK and will take up the new position in September 2022.

“As Xspray Pharma takes steps towards a sharp commercialization phase and the work on our project portfolio continues, we are now appointing the newly established position Chief Medical Officer. Thomas' solid experience in oncology and clinical trials makes him exceptionally suitable for the medical responsibility at Xspray Pharma. We welcome Thomas to the management team and look forward to working together.” says Per Andersson, CEO of Xspray Pharma.

Thomas was previously the Head of Department of Oncology at Karolinska University Hospital and has extensive experience in from the pharmaceutical industry. He most recently joins from the position as the Nordic Medical Director of Oncology at GSK. Thomas is a specialist in oncology and associate professor at Linköping University and has an MBA from the Stockholm School of Economics.

“What Xspray Pharma has achieved so far with its innovative technology is truly impressive. I look forward to working with Xspray Pharma's strong team and being able to contribute with my experiences from the pharmaceutical industry and from having worked clinically with cancer patients for over 25 years,” says Thomas Walz.

The new role will include establishing Xspray Pharma’s global Medical Affairs function, preparing the launch of the first products and the overall responsibility for clinical development plans.

Thomas joins on September 1st and will be part of Xspray Pharma's management team.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com